Home › Linfoma a cellule del mantello › Texas › Houston
Studi clinici su Linfoma a cellule del mantello a Houston, TX
15 studi su Linfoma a cellule del mantello cercano partecipanti presso sedi a Houston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
In reclutamentoFase 1/2
- Research Site, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
In reclutamentoFase 3
- Md Anderson Cancer Center, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
In reclutamentoFase 1/2
- Md Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
In reclutamentoFase 1/2
- Research Site, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
In reclutamentoFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
In reclutamentoFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
In reclutamentoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
In reclutamentoFase 2
- M D Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
In reclutamentoFase 2Volontari sani benvenuti
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
In reclutamentoFase 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Houston
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
In reclutamentoFase 2
- M D Anderson Cancer Center, Houston
Studi su Linfoma a cellule del mantello in altre città
- Baldwin Park, CA15 studi
- Durham, NC13 studi
- New York City, NY12 studi
- Seattle, WA12 studi
- Milwaukee, WI12 studi
- Boston, MA11 studi
- Columbus, OH11 studi
- Nashville, TN11 studi
- Chicago, IL10 studi
- Portland, OR9 studi
- Rochester, MN9 studi
- St. Louis, MO8 studi
Altri studi a Houston
- Cancro del polmone non a piccole cellule145 studi
- Cancro al seno126 studi
- Cancro (tutti i tipi)121 studi
- Cancro metastatico104 studi
- Cancro colorettale102 studi
- Cancro ovarico89 studi
- Leucemia mieloide acuta85 studi
- Cancro ai polmoni78 studi
- Cancro alla prostata76 studi
- Cancro dell'endometrio68 studi
- Cancro pancreatico61 studi
- Melanoma59 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.